1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)

 
• By Michael McCaughan

CMS’ coverage policy on erythropoietin has huge commercial implications for Amgen and J&J. It is also a wake-up call for the rest of the industry: there are now two regulators who control the keys to success in the pharmaceutical industry.

Michael McCaughan

The Centers for Medicare & Medicaid Services is about to make a decision that could cost Amgen Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D